Stifel Nicolaus maintained Sabra Health Care REIT SBRA with a Buy rating and raised the price target from $29.00 to $30.00.
Stifel Nicolaus analyst Robert Mains wrote, "Yesterday, Sabra priced 5 million shares of 7.125% cumulative redeemable preferred stock at $25. The deal was upsized considerably from 2 million shares. Assuming an additional 750,000 shares for the underwriters' overallotment, Sabra will use net proceeds of $138.2 million to pay down its revolver ($92.5 million outstanding as of December 31) and to fund future acquisitions. […] We had modeled Sabra raising $100 million this year through an at-the-market equity program. In our view, the preferred offering obviates the need for additional equity capital until 2014."
Sabra Health Care REIT closed at $28.40 on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in